Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02843165 · ClinicalTrials.gov registry record · Phase 2
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
A Phase 2 study of Metastatic Cancer, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT02843165 is a Phase 2 study of Metastatic Cancer that has completed, run by University of California, San Diego. The registered enrollment target is 106 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02843165, a Phase 2 study of Metastatic Cancer, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in patients with advanced metastatic cancer.
Conditions Studied
Interventions
- DRUG Checkpoint blockade immunotherapy
- RADIATION Checkpoint blockade immunotherapy plus SBRT
Study Locations (1)
California
- UCSD Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-09-02 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02843165
The ClinicalTrials.gov registry entry for NCT02843165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (76% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Checkpoint blockade immunotherapy is the first listed.
NCT02843165 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02843165 about?
NCT02843165 is a clinical study titled "Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease". The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in patients with advanced metastatic cancer.
What is the current status of trial NCT02843165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2016-09-02. Estimated completion is 2024-08-15.
What conditions does trial NCT02843165 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT02843165?
The interventions under investigation include: Checkpoint blockade immunotherapy (DRUG), Checkpoint blockade immunotherapy plus SBRT (RADIATION).
Who is sponsoring clinical trial NCT02843165?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02843165 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.